AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Qulipta (atogepant) by Quarter
Qulipta (atogepant) — Worldwide reported growth YoY (%) (%)
AbbVie Qulipta (atogepant): 30.9% in Q2 2026, down 46.6 pts from a year earlier. That is the lowest of the 10 quarters on record here.
Latest, Q2 2026
30.9%
Period ended Jun 30, 2026
Change on a year earlier
-46.6 pts
77.5% in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
“| 30.9 | 95.9 | 30.3”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Qulipta (atogepant) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.9% | -46.6 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 53.6% | +6.0 pts | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 42.6% | -33.8 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 64.1% | +30.5 pts | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 77.5% | +21.2 pts | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 47.6% | -50.1 pts | Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗ |
| Q4 2024 | Dec 31, 2024 | 76.4% | – | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| Q3 2024 | Sep 30, 2024 | 33.6% | – | Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 56.3% | – | Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | 97.7% | – | Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗ |
Cite this data
StockData. (2026). AbbVie Qulipta (atogepant) (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/qulipta-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.